TITLE

Merck & Co: Isentress approval, another first for the HIV market

PUB. DATE
December 2007
SOURCE
PharmaWatch: Monthly Review;Dec2007, Vol. 6 Issue 12, p27
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of Merck & Co.'s Isentress combined with other antiviral agents in treating HIV patients facing resistance to multiple HIV drugs by U.S. Food and Drug Adminstration (FDA). Merck has priced the drug lower than Pfizer's Celsentri and Roche's Fuzeon, the other first-in-class therapy targeting patient group. Merck's proactive approach in promising further trials and investment in reporting systems could bolster the drug's commercial prospects.
ACCESSION #
27786746

 

Related Articles

  • FDA OKs Integrase Inhibitor for Treatment-Naive HIV-Infected Patients. Kaye, Donald // Clinical Infectious Diseases;9/1/2009, Vol. 49 Issue 5, pi 

    The article reports on the approval given by Food and Drug Administration (FDA) on the use of raltegravir in treating HIV-infected patients in the U.S. The regulators have approved the integrase inhibitor for HIV treatment to widen its use. According to Merck & Co. Inc., they also discovered...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Sep2007, Vol. 21 Issue 9, p702 

    The article offers news briefs related to antiviral agents in the U.S. The Selzentry tablet, a CCR5 antagonist from Pfizer Inc., was approved by the Food and Drug Administration (FDA). The Antiviral Drugs Advisory Committee of FDA voted to recommend the approval of Isentress, a raltegravir in...

  • Maraviroc for Treatment-Naive Patients with HIV-1 Infection: Is the Glass Half Empty or Half Full? Sax, Paul E. // Journal of Infectious Diseases;3/15/2010, Vol. 201 Issue 6, p797 

    In this article the author discusses the concerns related to maraviroc, a treatment for HIV-infected patients. It mentions that the approved maraviroc, by the U.S. Food and Drug Administration, is said to be used to treat patients using CCR5 receptor (R5 virus). It states that the downside of...

  • One-day, one-dose herpes treatments OK'd.  // Drug Topics;8/21/2006, Vol. 150 Issue 16, p8 

    The article reports that the drug Faciclovir has been approved in the U.S. as a single-day treatment for recurrent genital herpes and as a single-dose treatment for recurrent herpes labialis, both in immunocompetent patients. It was stated that this marks the first time an intiviral has been...

  • POSITIVE THINKING with Noel Walsh.  // Gay Community News;Jun2007, Issue 210, p24 

    The article shares the author's insights about the good news regarding the HIV medications. The author cites that the U.S. Food and Drug Administration has recommended the approval of a new class of anti-HIV drug, the CCR5 inhibitor maraviroc, for heavily treatment-experienced patients. He also...

  • Patient Adherence To HAART Regimens: Challenges For Physician Assistants And Health Care Providers. Day, Marvin // Internet Journal of Academic Physician Assistants;2003, Vol. 3 Issue 1, p42 

    Patients often adhere incompletely and inadequately to highly active antiretroviral therapy (HAART) regimens used in the treatment of HIV infection. This permits the emergence of HIV variants that are resistant to current treatment. The physician assistant often assumes the responsibility for...

  • Comparative Cost-Efficacy Analysis of Darunavir/ritonavir and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in the United States. Brogan, Anita J.; Mrus, Joseph; Hill, Andrew; Sawyer, Anthony W.; Smets, Erik // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p133 

    Purpose: A comprehensive study comparing the costs and efficacies of darunavir/ritonavir 800/100 mg qd and the other ritonavir-boosted (/r) protease inhibitors (PIs) recommended for treatment-naïve individuals with HIV-1 infection would help health care decision makers identify the value of...

  • Gilead's Once-Daily Single Tablet Regimen Complera(r) Maintains HIV Suppression Among Patients Switching From Protease Inhibitor-Based Regimens.  // Biomedical Market Newsletter;7/26/2012, Vol. 21, p1 

    The article presents information that Gilead Sciences Inc. has revealed a data of the phase three clinical trial of the Complera that evaluated virologically suppressed treatment which has been experienced by the HIV patients. It informs that Complera has been approved by the U.S. Food and Drug...

  • Merck Wins U.S. Priority Review for HIV Drug.  // Clinical Infectious Diseases;9/1/2007, Vol. 45 Issue 5, piv 

    The article reports on the priority review status granted by the U.S. Food and Drug Administration (FDA) to Merck & Co. Inc. for its experimental HIV drug Isentress. Accordingly, the company is very glad with the opportunity and expects a decision on the experimental drug by mid-October 2007....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics